Shilpa Biologicals and Orion Partner to Develop Nivolumab Biosimilar for Europe
Shilpa Medicare's subsidiary, Shilpa Biologicals, has partnered with Finland-based Orion Corporation to co-develop and supply an intravenous nivolumab biosimilar for the European market. Orion will exclusively register, market, and sell the biosimilar, while Shilpa Biologicals will lead development and manufacture it at its Dharwad facility. The agreement includes milestone payments and long-term supply revenue for Shilpa. Nivolumab, a widely used cancer immunotherapy, generated about $4.1 billion in European sales in 2025, with the partnership aiming to expand patient access post-originator exclusivity loss.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. Coverage leans balanced overall (Left 0%, Centre 100%, Right 0%). Overall sentiment is positive (75/100). Lens Score 34/100 — low public interest.
Outlets analysed (first-hand measurement by TBN's Bias Engine):
- businessstandard— balanced framing, positive sentiment
- businessstandard— balanced framing, positive sentiment
- businessstandard— balanced framing, positive sentiment
AI Analysis
The articles primarily present a business and pharmaceutical industry perspective, focusing on corporate partnership and market opportunities without political framing. The coverage highlights company statements and market reactions, reflecting a neutral, economic development viewpoint without partisan or ideological bias.
The tone across the articles is generally positive, emphasizing the strategic partnership, market potential, and stock price gains. The coverage highlights growth prospects and expanded patient access, with no critical or negative sentiment evident, reflecting an optimistic but factual reporting style.
How 3 sources covered this story
Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.